RASGEF1C

Across TCGA pan-cancer cohorts, RASGEF1C RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated RASGEF1C data layer compared with 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RASGEF1C RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RASGEF1C expression acts as an unfavorable survival marker, although some lineages such as LGG and ACC show a favorable association.

LUAD, LGG, and KICH are the cancer types where RASGEF1C RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.589	0.733	<.001	60	view →
LGG	DFS	Median	All	0.821	0.654	<.001	54	view →
KICH	DFS	Median	II,III,IV	0.447	0.947	<.001	51	view →
LIHC	OS	Median	III,IV	0.320	0.676	<.001	35	view →
ACC	DFS	Tertile	IV	0.668	0.100	.001	30	view →
KIRC	OS	Median	All	0.556	0.707	<.001	30	view →
HNSC	DFS	Quartile	III,IV	0.758	0.428	.001	28	view →
ESCA	OS	Quartile	All	1.000	0.341	.009	24	view →
BLCA	DFS	Quartile	II,III,IV	0.260	0.387	.013	18	view →
UCS	DFS	Median	All	0.317	0.550	.022	16	view →
UVM	DFS	Quartile	III,IV	0.864	0.388	.010	12	view →
THCA	DFS	Median	All	0.926	0.863	.013	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

RASGEF1C–LUAD (DFS)

Open the LUAD breakdown →